Pathological and biochemical effects of therapeutic and supratherapeutic doses of celecoxib in Wistar albino male rats

References

• Aldana, L., De Mejia, E. G., Craigmill, A., Tsutsumi, V., Armenmdariz-Borunda, J., Panduro, A., et al. (1998). Cypermethrin increases apo A-1 and apo B mRNA but not hyperlipidemia in rats. Toxicol Lett 95:31–39.
   PubMed Web of Science ®Google Scholar
• Chow, L. W. C., Cheng, C. W. L., Wong, J. L. N., Toi, M. (2005). Serum lipid profiles in patients receiving endocrine treatment for breast cancer—the results from the Celecoxib Antiaromatase Neoadjuvant (CAAN) trial. Biomed Pharmacother 59:S302–S305.
   Google Scholar
• Chulada, P. C., Thompson, M. B., Mahler, J. F., Doyle, C. M., Gaul, B. W., Lee, C., et al. (2000). Genetic distruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705–4708.
   PubMed Web of Science ®Google Scholar
• Davies, N. M., McLachlan, A. J., Day, R. O., Williams, K. M. (2000). Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclooxygenase-2 inhibitor. Clin Pharmacokinet 38:225–242.
   PubMed Web of Science ®Google Scholar
• Dempke, W., Rie, C., Grothey, A., Schmoll, H. J. (2001). Cyclooxygenase-2: novel target for cancer chemotheraphy. J Cancer Res Clin Oncol 127:411–417.
   PubMed Web of Science ®Google Scholar
• Emery, P., Zeidler, H., Kvien, T. K., Guslandi, M., Naudin, R., Stead, H., et al. (1999). Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised, double-blind comparison. Lancet 354:2106–2111.
   PubMed Web of Science ®Google Scholar
• Grieco, A., Miele, L., Giorgi, A., Civello, I. M., Gasbarrini, G. (2002). Acute cholestatic hepatitis associated with celecoxib. Ann Pharmacother 36:1887–1889.
   PubMed Web of Science ®Google Scholar
• Han, C., Leng, J., Demetris, A. J., Wu, T. (2004). Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2–independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 64:1369–1376.
   Web of Science ®Google Scholar
• Hasegawa, K., Ichikawa, W., Fujita, T., Ohno, R., Okusa, T., Yoshinaga, K., et al. (2001). Expression of cyclooxygenase-2 (COX-2) mRNA in human colorectal adenomas. Eur J Cancer 37:1469–1474.
   PubMed Web of Science ®Google Scholar
• Hawkey, C. J. (1999). COX-2 inhibitors. Lancet 353:307–314.
   PubMed Web of Science ®Google Scholar
• Hull, M. A., Booth, J. K., Tisbury, A., Scott, N., Bonifer, C., Markham, A. F., et al. (1999). Cyclooxygenase 2 is upregulated and localized to macrophages in the intestine of Min mice. Br J Cancer 79:1399–1405.
   PubMed Web of Science ®Google Scholar
• Jones, D. A., Carlton, D. P., McIntyre, T. M., Zimmerman, G. A., Prescott, S. M. (1993). Molecular cloning of human prostoglandin endoperoxide synthatase type II and demonstration of expression in response to cytokines. J Biol Chem 208:9049–9054.
   Google Scholar
• Maier, T. J., Schilling, K., Schmidt, R., Geisslinger, G., Grosch, G. (2004). Cyclooxygenase-2 (COX-2)–dependent and –independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67:1469–1478.
   PubMed Web of Science ®Google Scholar
• Marquez-Rosado, L., Trejo-Solis, M. C., Garcia-Cuellar, C. M., Villa-Trevino, S. (2005). Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats. J Hepatol 43:653–660.
   PubMed Web of Science ®Google Scholar
• Masferrer, J. L., Isakson, P. C., Seibert, K. (1996). Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tract. Gastroenterol Clin N Am 25:363–372.
   PubMed Web of Science ®Google Scholar
• National Research Council. (1996). Guide for the care and use of laboratory animals. Washington, DC: National Academy.
   Google Scholar
• O’Beirne, J. P., Cairns, S. R. (2001). Cholestatic hepatitis in association with celecoxib. BMJ 323:23.
   PubMed Web of Science ®Google Scholar
• Prescott, S. M., Fitzpatrick, F. A. (2000). Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470:M69–M78.
   Google Scholar
• Ravoori, S., Feng, Y., Neale, J. R., Jeyabalan, J., Srinivasan, C., Hein, D. W., et al. (2008). Dose-dependent reduction of 3,2’-dimethyl-4-aminobiphenyl–derived DNA adducts in colon and liver of rats administered celecoxib. Mutat Res 638:103–109.
   PubMed Web of Science ®Google Scholar
• Sonoshita, M., Takaku, K., Oshima, M., Sugihara, K., Taketo, M. M. (2002). Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res 62:6846–6849.
   PubMed Web of Science ®Google Scholar
• Tiano, H. F., Loftin, C. D., Akunda, J., Lee C. A., Spalding, J., Sessoms, A., et al. (2002). Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 62:3395–3401.
   PubMed Web of Science ®Google Scholar
• Wong, B. C., Jiang, X., Fan, X. M., Lin, M. C., Jiang, S. H., Lam, S. K., et al. (2003). Suppression of RelA/p65 nuclear translocation independent of kappaB-alpha degradation by cyclooxygenase-2 inhibitor in gastric cancer. Oncogene 22:1189–1197.
   PubMed Web of Science ®Google Scholar